Your browser doesn't support javascript.
loading
Presurgical Use of Cenobamate for Adult and Pediatric Patients Referred for Epilepsy Surgery: Expert Panel Recommendations.
Laxer, Kenneth D; Elder, Christopher J; Di Gennaro, Giancarlo; Ferrari, Louis; Krauss, Gregory L; Pellinen, Jacob; Rosenfeld, William E; Villanueva, Vicente.
Affiliation
  • Laxer KD; Sutter Pacific Epilepsy Program, California Pacific Medical Center, 1100 Van Ness Ave, 6th floor, San Francisco, CA, 94109, USA. laxerkd@sutterhealth.org.
  • Elder CJ; NYU Langone Health Comprehensive Epilepsy Center, New York, NY, USA.
  • Di Gennaro G; IRCCS NEUROMED, Pozzilli, IS, Italy.
  • Ferrari L; SK Life Science, Inc., Paramus, NJ, USA.
  • Krauss GL; Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Pellinen J; University of Colorado School of Medicine, Aurora, CO, USA.
  • Rosenfeld WE; Comprehensive Epilepsy Care Center for Children and Adults, St. Louis, MO, USA.
  • Villanueva V; Refractory Epilepsy Unit, Hospital Universitari I Politècnic La Fe, Valencia, Spain.
Neurol Ther ; 2024 Aug 18.
Article in En | MEDLINE | ID: mdl-39154302
ABSTRACT
Cenobamate has demonstrated efficacy in patients with treatment-resistant epilepsy, including patients who continued to have seizures after epilepsy surgery. This article provides recommendations for cenobamate use in patients referred for epilepsy surgery evaluation. A panel of six senior epileptologists from the United States and Europe with experience in presurgical evaluation of patients with epilepsy and in the use of antiseizure medications (ASMs) was convened to provide consensus recommendations for the use of cenobamate in patients referred for epilepsy surgery evaluation. Many patients referred for surgical evaluation may benefit from ASM optimization; both ASM and surgical treatment should be individualized. Based on previous clinical studies and the authors' clinical experience with cenobamate, a substantial proportion of patients with treatment-resistant epilepsy can become seizure-free with cenobamate. We recommend a cenobamate trial and ASM optimization in parallel with presurgical evaluations. Cenobamate can be started before phase two monitoring, especially in patients who are found to be suboptimal surgery candidates. As neurostimulation therapies are generally palliative, we recommend trying cenobamate before vagus nerve stimulation (VNS), deep brain stimulation, or responsive neurostimulation (RNS). In surgically remediable cases (mesial temporal sclerosis, benign discrete lesion in non-eloquent cortex, cavernous angioma, etc.), cenobamate use should not delay imminent surgery; however, a patient may decide to defer or even cancel surgery should they achieve sustained seizure freedom with cenobamate. This decision should be made on an individual, case-by-case basis based on seizure etiology, patient preferences, potential surgical risks (mortality and morbidity), and likely surgical outcome. The addition of cenobamate after unsuccessful surgery or palliative neuromodulation may also be associated with better outcomes.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Neurol Ther Year: 2024 Document type: Article Affiliation country: Estados Unidos Publication country: NEW ZEALAND / NOVA ZELÂNDIA / NUEVA ZELANDA / NZ

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Neurol Ther Year: 2024 Document type: Article Affiliation country: Estados Unidos Publication country: NEW ZEALAND / NOVA ZELÂNDIA / NUEVA ZELANDA / NZ